US 12,246,013 B2
Vasoconstriction compositions and methods of use
Gerald Horn, Deerfield, IL (US)
Assigned to EYE THERAPIES LLC, Dana Point, CA (US)
Filed by Eye Therapies, LLC, Dana Point, CA (US)
Filed on Aug. 22, 2018, as Appl. No. 16/108,727.
Application 16/108,727 is a continuation in part of application No. 12/460,967, filed on Jul. 27, 2009, abandoned.
Claims priority of provisional application 61/207,481, filed on Feb. 12, 2009.
Claims priority of provisional application 61/203,120, filed on Dec. 18, 2008.
Claims priority of provisional application 61/192,777, filed on Sep. 22, 2008.
Claims priority of provisional application 61/137,714, filed on Aug. 1, 2008.
Prior Publication US 2018/0360825 A1, Dec. 20, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/498 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/40 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/498 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/0073 (2013.01); A61K 9/08 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61P 27/02 (2018.01)] 10 Claims
 
1. A method selected from the group consisting of reversing rebound hyperemia, reducing eye redness, increasing eye whiteness and a combination thereof, comprising topically administering to a subject in need thereof a composition comprising from about 0.01% to about 0.015% w/v brimonidine or a pharmaceutically acceptable salt thereof, wherein w/v denotes weight by total volume of the composition.